SCHEMBL3772613

SCHEMBL3772613

Clc1ccc(-c2csc(Br)n2)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.54
AMY1A P0DUB6 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 2/20 0.52
RAB9A P51151 2/20 0.52
NPC1 O15118 1/20 0.52
CRHBP P24387 1/20 0.52
CRHR2 Q13324 1/20 0.52
MAOB P27338 4/20 0.51
MAOA P21397 3/20 0.51
MAPT P10636 3/20 0.48
HSP90AA1 P07900 2/20 0.47
HSP90AB1 P08238 2/20 0.47
C1S P09871 1/20 0.46
LMNA P02545 4/20 0.45
GAA P10253 2/20 0.44
EGFR P00533 1/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
XBP1 P17861 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29519297 0.82 AMY1A (0.61) ARAMY1ASMN1; SMN2KDM4ERAB9A
SCHEMBL129994 0.82 AMY1A (0.61) ARAMY1ASMN1; SMN2KDM4ERAB9A
Bromide SCHEMBL8355183 0.81 AMY1A (0.59) ARAMY1ASMN1; SMN2KDM4ERAB9A
SCHEMBL8803920 0.81 AR (0.52) ARAMY1ASMN1; SMN2KDM4ERAB9A
SCHEMBL8698255 0.81 MAPT (0.53) ARAMY1ASMN1; SMN2KDM4ERAB9A
SCHEMBL9849025 0.80 SMN1; SMN2 (0.51) ARAMY1ASMN1; SMN2KDM4ERAB9A
SCHEMBL14378910 0.78 KDM4E (0.75) ARAMY1ASMN1; SMN2KDM4ERAB9A
SCHEMBL30378574 0.78 CYP19A1 (0.58) SMN1; SMN2KDM4ERAB9ANPC1MAPT
SCHEMBL3772673 0.78 CYP19A1 (0.58) SMN1; SMN2KDM4ERAB9ANPC1MAPT
SCHEMBL31006091 0.77 AMY1A (0.63) AMY1ASMN1; SMN2RAB9ANPC1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 AR 2900/4885AMY1A 3263/4885SMN1; SMN2 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.